Close menu

December 23rd, 2022 | 08:00 CET

BioNxt Solutions, MorphoSys, BioNTech - Innovations and scaling potential for the portfolio

  • Biotechnology
Photo credits:

Around the world, patients are used to swallowing medicines in pill form. Sales of oral, fixed-dose drugs alone accounted for a whopping 23.8% of the global pharmaceutical drug delivery market in 2021. That is reason enough for Canadian biotech company BioNxt Solutions to further expand its strategic pole position. BioNxt Solutions secures further rights to a unique platform technology in this segment. Caution is currently the order of the day for MorphoSys. Analysts downgrade the target price from EUR 16 to EUR 12 after a disappointing Q3. BioNTech, on the other hand, can expand its dominance. The Mainz-based company is scaling up in the Asia-Pacific region with new production sites.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: BioNxt Solutions Inc. | CA0909741062 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNxt Solutions - Acquisition of additional technology platform for strategic expansion

    Since the Covid pandemic, investors know how intensively the development speed of a vaccine can affect company profits. Pfizer, Moderna and BioNTech have proven it: Digitization has reached the pharmaceutical industry. Where research and development cycles of about 10 years usually dominate, platform technologies now provide an opportunity to drive product commercialization rapidly.

    The Canadian biotech company BioNxt (formerly XPhyto) is excellently positioned with its portfolio. Its business model includes point-of-care diagnostics, innovative drug delivery methods, and the mental health space with breakthrough compounds.

    The faster the active ingredients of drugs enter the bloodstream and take effect, the sooner patients are helped. Orally administered drugs in particular are prescribed most frequently worldwide. Revenue from the sale of oral, fixed-dose drugs accounted for 23.8% of the global pharmaceutical drug delivery market in 2021. BioNxt (ISIN CA0909741062) is soon acquiring additional rights to a platform with a novel coating technology for solid oral dosage forms. "We are delighted to add another drug delivery platform to the technology portfolio," said Hugh Rogers, CEO & Director of BioNxt. "This novel coating system could significantly improve oral drug delivery in the form of tablets and capsules by providing more precise and predictable dosing. We see a wide range of potential applications, from dietary supplements and over-the-counter medications to prescription drugs and psychedelic substances."

    The global oral solid dosage market was valued at USD 524.6 billion in 2021 and is expected to reach USD 1.03 trillion by the end of 2032, growing rapidly at a CAGR of 6.4% during the study period 2022-2032, according to Fact.MR Research & Consulting.

    MorphoSys - Target Price falls from EUR 16 to EUR 12, CFO resigns

    The German company MorphoSys (ISIN DE0006632003) is currently experiencing stormy times. Goldman Sachs downgrades the Company from "neutral" to "sell". Their analysts forecast a price target of EUR 12.00. The reason given is the disappointing third quarter, increased competition and little chance of profit in the coming twelve months. Over the current year, the MorphoSys share fell by a whopping 62.82%.

    In November, the Company suffered a major setback as an Alzheimer's drug candidate they developed in collaboration with Roche failed to meet its goal of slowing the progression of the memory-robbing disease in two separate trials.

    Now, in addition, the chief financial officer is leaving the Company for personal reasons in March 2023. Sung Lee joined MorphoSys in Germany in February 2021. Through the acquisition of Constellation Pharmaceuticals, Sung helped build the Company's future growth and strengthened the pipeline with the first-line drug for myelofibrosis, a malignant bone marrow disease.

    "The last two years have been an exciting time for MorphoSys as we sharpened the Company's strategy and accelerated our goal to become a leader in hematology oncology," said Sung Lee, Chief Financial Officer of MorphoSys. MorphoSys is committed to improving the lives of cancer patients. Its departments are located in Planegg, near Munich, Germany, and in Boston, MA, USA.

    BioNTech - On track for growth in the Asia-Pacific region

    A competitor on the radar in cancer therapy is BioNTech (ISIN US09075V1026), a biotech company based in Mainz, Germany. The Company will accelerate and expand the clinical development of its cancer immunotherapy pipeline in Asia-Pacific by increasing its manufacturing capacity in the region.

    The first regional clinical trial sites will initially evaluate head and neck cancer candidates in Taiwan for novel cancer immunotherapies. BNT113 is expected to be the first of a "potential wave of novel cancer immunotherapies." The German company is bringing Taiwan's YongLin Healthcare Foundation and Retain Biotech AG on board to further develop plans for genomic medicine in oncology.

    Last month, the parties signed a memorandum of understanding to develop this medical direction further. The YongLin Healthcare Foundation is funding this organization, which is involved in precision medicine and cell therapy. The Australian site in Melbourne is also earmarked as a launching point to develop the Pacific region.

    In addition, BioNTech announced plans to establish an end-to-end clinical-scale mRNA production facility in Melbourne based on the BioNTainer solution to provide access to mRNA technology and foster research collaborations in the Asia-Pacific region. BioNTech has already established subsidiaries in Singapore, Shanghai and Melbourne. In addition, a representative office has been registered in Taipei, which is expected to become part of the Company's global network as regional innovation centers. These locations are expected to create hundreds of jobs in various functions by 2024.

    The rally for the best possible digitization of the production process of pharmaceuticals and the associated rapid commercialization currently seems to be leading with BioNxt Solutions. The Company focuses on platform technology for oral drugs. MorphoSys, with its focus on oncology, has to be patient. After the setback with Roche, the CFO is now leaving the Company, and analysts are lowering the target price to EUR 12. BioNTech, on the other hand, is expanding its business in the Asia-Pacific region through collaborations and new production sites. The scaling opportunities of oral pharmaceuticals, oncology and the provision of production sites for mRNA active ingredients seem unlimited.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.